- Home
- WLGS vs CRBP Comparison
WLGS vs CRBP Comparison
Compare WLGS & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- CRBP
- Stock Information
- Founded
- WLGS 1981
- CRBP 2009
- Country
- WLGS Hong Kong
- CRBP United States
- Employees
- WLGS N/A
- CRBP N/A
- Industry
- WLGS Engineering & Construction
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- WLGS Consumer Discretionary
- CRBP Health Care
- Exchange
- WLGS Nasdaq
- CRBP Nasdaq
- Market Cap
- WLGS 125.5M
- CRBP 103.6M
- IPO Year
- WLGS 2023
- CRBP N/A
- Fundamental
- Price
- WLGS $4.91
- CRBP $8.18
- Analyst Decision
- WLGS
- CRBP Strong Buy
- Analyst Count
- WLGS 0
- CRBP 8
- Target Price
- WLGS N/A
- CRBP $61.38
- AVG Volume (30 Days)
- WLGS 503.1K
- CRBP 296.4K
- Earning Date
- WLGS 03-04-2025
- CRBP 03-11-2025
- Dividend Yield
- WLGS N/A
- CRBP N/A
- EPS Growth
- WLGS N/A
- CRBP N/A
- EPS
- WLGS 0.02
- CRBP N/A
- Revenue
- WLGS $7,272,879.00
- CRBP N/A
- Revenue This Year
- WLGS N/A
- CRBP N/A
- Revenue Next Year
- WLGS N/A
- CRBP N/A
- P/E Ratio
- WLGS $279.25
- CRBP N/A
- Revenue Growth
- WLGS 66.93
- CRBP N/A
- 52 Week Low
- WLGS $0.44
- CRBP $7.64
- 52 Week High
- WLGS $9.66
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- WLGS 38.51
- CRBP 35.10
- Support Level
- WLGS $3.59
- CRBP $7.64
- Resistance Level
- WLGS $9.09
- CRBP $9.51
- Average True Range (ATR)
- WLGS 1.29
- CRBP 0.84
- MACD
- WLGS -0.51
- CRBP -0.05
- Stochastic Oscillator
- WLGS 21.75
- CRBP 13.71
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.